Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$27,000.00
Investigating the Pharmacological Modulation of Dopamine in Glioblastoma Progression in Mice
EF 2024-25
Résumé
Glioblastoma (GBM) is an aggressive and common type of brain tumour with an alarmingly low survival rate. A significant challenge in treating GBM is the presence of cancer stem cells, known as glioblastoma stem cells (GSCs), which drive tumour growth and contribute to the cancer's resistance to therapies. This research aims to investigate the role of dopamine (DA), a neurotransmitter that regulates movement and motivation in the central nervous system, in influencing GSCs and GBM progression. Emerging evidence suggests that DA can affect the proliferation of neural precursor cells, and alterations in DA levels might play a role in the development of brain tumours. Notably, individuals with Parkinson disease, a condition characterized by low DA levels, are at a lower risk of developing GBM. Our preliminary findings suggest that reducing DA in specific regions of the brain can prevent GBM formation. To build on these insights, this project will use a genetically engineered mouse model to explore how manipulating DA levels affects GBM progression. By administering drugs that increase or decrease DA levels, we will examine how these changes influence GSC behaviour, including cell proliferation and migration. We will also assess the impact of DA modulation on neural stem cells, both in healthy mice and in those with GBM-related mutations. Ultimately, we aim to determine whether altering DA levels pharmacologically can slow or halt GBM progression. Since several DA-modulating drugs are already approved for clinical use and are well-tolerated, this research could offer rapid pathways to new treatments for GBM, providing hope for better outcomes for patients.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
529928
Name
Tymofyeyeva Anna
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating the Pharmacological Modulation of Dopamine in Glioblastoma Progression in Mice
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer Stem Cells; Central Nervous System; Dopamine; Genetic Mutations; Glioblastoma; In Vivo; Lineage Tracing; Mouse Model; Pharmacological Therapy; Tumour Growth Inhibition
Abstract
Glioblastoma (GBM) is an aggressive and common type of brain tumour with an alarmingly low survival rate. A significant challenge in treating GBM is the presence of cancer stem cells, known as glioblastoma stem cells (GSCs), which drive tumour growth and contribute to the cancer's resistance to therapies. This research aims to investigate the role of dopamine (DA), a neurotransmitter that regulates movement and motivation in the central nervous system, in influencing GSCs and GBM progression. Emerging evidence suggests that DA can affect the proliferation of neural precursor cells, and alterations in DA levels might play a role in the development of brain tumours. Notably, individuals with Parkinson disease, a condition characterized by low DA levels, are at a lower risk of developing GBM. Our preliminary findings suggest that reducing DA in specific regions of the brain can prevent GBM formation. To build on these insights, this project will use a genetically engineered mouse model to explore how manipulating DA levels affects GBM progression. By administering drugs that increase or decrease DA levels, we will examine how these changes influence GSC behaviour, including cell proliferation and migration. We will also assess the impact of DA modulation on neural stem cells, both in healthy mice and in those with GBM-related mutations. Ultimately, we aim to determine whether altering DA levels pharmacologically can slow or halt GBM progression. Since several DA-modulating drugs are already approved for clinical use and are well-tolerated, this research could offer rapid pathways to new treatments for GBM, providing hope for better outcomes for patients.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Tymofyeyeva, Anna
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~